# What Benefits and Harms Did Semaglutide Studies Find? > Semaglutide: Research Peptide Fundamentals research peptides — Learn what large semaglutide studies found and which harms still matter. Research Peptide Fundamentals research peptides **SEMAGLUTIDE / 02 — HUMAN STUDIES** Thousands of people took part. The studies found benefits, stomach trouble, and limits that still matter to you. ## Why did drug makers create semaglutide? Drug makers created semaglutide (Ozempic, Wegovy) to make GLP-1 last longer. This gut hormone helps control your blood sugar and hunger. Semaglutide became an approved prescription medicine for set uses. Unlike the other three compounds here, it has large human studies to help you judge it. One study followed people who had excess weight but did not have diabetes for 68 weeks. Average weight loss was greater with semaglutide than with placebo [11]. Another study found fewer major heart and blood-vessel problems in people at high risk [10]. Kidney and heart results also improved in people with lasting kidney disease plus type 2 diabetes [9]. Strong proof doesn't mean that you will benefit or face little risk. Benefits and harms both come from human studies here [12]. ## How is semaglutide different from the natural hormone? Drug makers changed a copy of a gut hormone into a 31-amino-acid drug. The hormone, called GLP-1, fades quickly in its natural form. Semaglutide breaks down more slowly and clings to a common blood protein. That design keeps GLP-1 action in your blood much longer. The studies used products made to strict standards. Another product sold under the same name may not match the drug tested in people. That matters before you ask whether the medicine works for you. The amount, purity, and way it is made affect what reaches your body. Semaglutide does more than change weight. Its GLP-1 action also affects blood sugar, while studies track heart and kidney health. ## What does semaglutide do inside the body? Semaglutide acts where the gut hormone GLP-1 would act on cells. When your blood sugar rises, the pancreas then releases more insulin. The medicine also reduces a hormone whose job is to push blood sugar upward. Food stays in your stomach longer as well. In the brain, semaglutide helps people feel full sooner and eat less. Human studies show how much weight changed in the groups tested. A slower stomach can explain nausea and changes in how pills enter the blood. Human studies tell you how often those problems happened. Slow breakdown and a link to a blood protein keep semaglutide working longer. That may help treatment, but an unwanted effect may also last longer. ## How much changed in the large human studies? The STEP 1 study enrolled 1,961 adults with excess weight but no diabetes. Chance decided whether each person received semaglutide or placebo. At 68 weeks, the paper's -14.9% and -2.4% figures mean average weight loss, not gain [11]. Those group averages do not predict your result. SELECT included 17,604 adults with heart and blood-vessel disease and excess weight, but no diabetes. Its 0.80 figure compares risk between groups; it is not a count of people helped [10]. FLOW included 3,533 people who had lasting kidney disease along with type 2 diabetes. Its 0.76 figure joins serious kidney trouble and death, rather than giving one plain count [9]. A study of 751 adults found more weight loss with tirzepatide at 72 weeks: -20.2% versus -13.7% [8]. Semaglutide still reduced weight, but less on average in that study. ## What did users report, and what did studies confirm? These are **reports from users, not effects checked in a controlled trial**. People mention less hunger, earlier fullness, weight loss, and better home sugar readings. They also report nausea, vomiting, constipation, diarrhea, heartburn, tiredness, odd burps, hair loss, dizziness, and shot soreness. Reports can't show how often a problem occurs or whether the drug caused it. Human studies give firmer safety facts. A review found mostly mild or moderate stomach and bowel trouble that often went away [12]. The review also found more gallbladder trouble, but the cited finding gives no plain extra count. Too few cases settled concerns about rare pancreas or thyroid cancer. Fast blood-sugar improvement may worsen some eye trouble, while large weight loss may include muscle. Weight often returns after the drug stops, so both points matter when you speak with your doctor. ## How sure are the semaglutide findings? Semaglutide has several large human studies with clear questions and long follow-up. They report benefits, harms, and one case where another drug worked better [8][9][10][11][12]. One careful human study may teach more than many mouse studies. Letting chance choose the care also helps separate the drug's effect from other causes. Still, each large study answers one question about one group. SELECT followed people at high risk for heart and blood-vessel trouble [10]. FLOW followed people with lasting kidney disease plus type 2 diabetes [9]. If your health differs, you may not receive the same size of benefit. Semaglutide has far more human proof than BPC-157, KPV, or MOTS-c. Claims about people need human studies made to test those claims. --- Null Peptides is an independent ledger of peptide signals and silences—not a clinic, a vendor, or a prescription.